Cargando…

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer

PURPOSE: Vascular endothelial growth factor receptor (VEGFR2) directed therapies result in a modest survival benefit for patients with advanced esophageal and gastroesophageal (GE) junction cancer. Platelet-derived growth factor receptor (PDGFR) may contribute to escape from VEGFR2 inhibition. We ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janjigian, Yelena Y., Vakiani, Efsevia, Ku, Geoffrey Y., Herrera, Jessica M., Tang, Laura H., Bouvier, Nancy, Viale, Agnès, Socci, Nicholas D., Capanu, Marinela, Berger, Michael, Ilson, David H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537304/ https://www.ncbi.nlm.nih.gov/pubmed/26275293 http://dx.doi.org/10.1371/journal.pone.0134731

Ejemplares similares

Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma
por: Tsai, Charlton, et al.
Publicado: (2022)

Perioperative versus total neoadjuvant chemotherapy in gastric cancer
por: Yang, Jessica, et al.
Publicado: (2023)

ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications
por: El Jabbour, Tony, et al.
Publicado: (2022)

Targeted next-generation sequencing of colorectal cancer identified metastatic specific genetic alterations
por: Brannon, A Rose, et al.
Publicado: (2012)

KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021)

Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
por: Chhabra, Arpit, et al.
Publicado: (2015)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
por: Ku, Geoffrey Y., et al.
Publicado: (2021)

Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract Cancers
por: Diplas, Bill H., et al.
Publicado: (2023)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
por: Van Cutsem, E., et al.
Publicado: (2021)

Refractory gastroesophageal reflux disease
por: Subramanian, Charumathi Raghu, et al.
Publicado: (2015)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Surgical Treatment of Gastroesophageal Junction Cancer
por: Hashimoto, Tadayoshi, et al.
Publicado: (2018)

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
por: Van Cutsem, E., et al.
Publicado: (2022)

Clinical Utility of (18)F-2-Fluoro-deoxy-d-glucose PET Imaging in Locally Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma
por: Cowzer, Darren, et al.
Publicado: (2023)

Integrative analysis of functional genomic annotations and sequencing data to identify rare causal variants via hierarchical modeling
por: Capanu, Marinela, et al.
Publicado: (2015)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease: Author's Reply
por: Hong, Su Jin
Publicado: (2013)

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer
por: Chau, Ian, et al.
Publicado: (2019)

Targeting EGFR in Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2020)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Case Report: Primary melanoma of the gastroesophageal junction
por: Hussein Agha, Yasmine, et al.
Publicado: (2020)

History of esophagectomy for cancer of the esophagus and the gastroesophageal junction
por: Lerut, Toni, et al.
Publicado: (2021)

A patient with gastroesophageal junction carcinoma and cough
por: Makkar, Priyanka S., et al.
Publicado: (2021)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
por: Mansoor, Wasat, et al.
Publicado: (2021)

Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer
por: Chau, Ian, et al.
Publicado: (2019)

Adenoid cystic carcinoma of the gastroesophageal junction: A case report
por: Shou, Chun-Hui, et al.
Publicado: (2019)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Sorafenib in patients with progressed and refractory bone tumors
por: Raciborska, Anna, et al.
Publicado: (2018)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

Role of tight junction proteins in gastroesophageal reflux disease
por: Mönkemüller, Klaus, et al.
Publicado: (2012)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Band ligation for a gastroesophageal junction Dieulafoy’s lesion
por: Benatta, Mohammed Amine, et al.
Publicado: (2017)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction
por: Kamarajah, S. K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vdetsrpa83299364hj8irukihg